Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" video here
在這裏觀看"這意味着什麼"視頻
Outlook CEO, Russ Trenary underscores that LYTENAVA (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD
Outlook Therapeutics首席執行官Russ Trenary強調LYTENAVA (bevacizumab gamma)已成爲第一種獲得歐洲委員會上市授權用於治療溼性年齡相關性黃斑變性的眼科製劑
FRENCHTOWN, NJ / ACCESSWIRE / June 6, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Outlook Therapeutics, Inc. (Nasdaq:OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases.
美國納斯達克上市的生物製藥公司Outlook Therapeutics, Inc.（股票代碼：Nasdaq:OTLK），專注於商業化和開發用於視網膜疾病治療的ONS-5010/LYTENAVA （bevacizumab-vikg；bevacizumab gamma）。JTC團隊是一家全面融合的企業傳播和投資者關係公司，今天發佈了一段虛擬投資者"這意味着什麼"片段，特別邀請Outlook Therapeutics的團隊進行了精彩的解讀。
As part of this "What This Means" segment, Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, discusses the Company's recently received European Commission Marketing Authorization for LYTENAVA (bevacizumab gamma) for the treatment of wet AMD.
在這個"這意味着什麼"片段中，Outlook Therapeutics的總裁兼首席執行官Russell Trenary討論了公司最近收到的關於LYTENAVA (bevacizumab gamma)用於溼性年齡相關性黃斑變性治療的歐洲委員會上市授權。
The Virtual Investor "What This Means" segment featuring Outlook Therapeutics is now available here. Additional videos from the "What This Means" series are available on demand at .
現在可以在這裏觀看Outlook Therapeutics的虛擬投資者"這意味着什麼"片段。"這意味着什麼"系列的其他視頻可按需獲取。
About JTC Team
關於JTC團隊
JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit or connect with the company on Twitter and LinkedIn.
JTC是一家全面融合的投資者關係公司，致力於幫助您向正確的受衆講述您的故事，以建立知名度。JTC以執行強大的傳播策略並取得成果而聞名。該公司與生命科學和科技行業的上市和非上市公司合作，以提高知名度並建立利益相關者價值。欲了解更多信息，請訪問網站或在Twitter和LinkedIn上與該公司聯繫。
Contact:
聯繫方式：
Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
jtc@jtcir.com
Jenene Thomas
JTC團隊有限責任公司
T：+1（833）475-8247
jtc@jtcir.com
SOURCE: JTC Team, LLC
消息來源：JTC團隊，LLC
譯文內容由第三人軟體翻譯。